EHA 2017 | Brentuximab vedotin combined with nivolumab for Hodgkin lymphoma
Stephen Ansell
• 22 Jun 2017
Stephen Ansell, MD, PhD, from the Mayo Clinic, Rochester, MN, USA, describes the positive results from a Phase II study on the treatment of Hodgkin lymphoma with nivolumab on three populations of patients: those who have received a transplant and therapy with brentuximab vedotin, those who have not received a transplant and those who have received a transplant without brentuximab vedotin therapy (NCT02572167). He adds that there is a need to confirm that these results are durable and treatment is effective in the long-term run, and there are studies that support this. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
